Market growth is expected to accelerate as local companies and multinational corporations expand their presence, leveraging Hong Kongs favorable business environment to capitalize on regional demand and technological advancements
At Embla, we help self-funded employers deliver better weight loss outcomes with a fraction of the medication cost all through a fully digital, turnkey solution that can go live in just 12 weeks
Choosing unsweetened varieties without added creamers or sugar is generally the healthier option
There are, at present, several once weekly GLP-1 receptor agonists available in the market: exenatide long-acting release (LAR), albiglutide, dulaglutide and semaglutide.74,75 Head-to-head clinical trials data suggest that long-acting GLP-1 receptor agonists produce superior glycemic control when compared with their shortacting counterparts (exenatide and liraglutide)
All Section At the first day of the 26th SMSNA Annual Fall Scientific Meeting, Dr